13

2026-03


Deepening Government–Enterprise Communication to Boost Industrial Development — Ai Li, Secretary of the Party Group and Director of the Standing Committee of the Daxing District People’s Congress, Led a Research Visit to Minhai Biotechnology.

On the morning of March 12, 2026, Ai Li, Party Secretary and Director of the Standing Committee of the District People’s Congress, led a delegation to the Daxing Biomedical Base. The group conducted an on-site visit and research at Beijing Minhai Biotechnology Co., Ltd. (hereinafter referred to as Minhai Bio), listened to the company’s development needs, and provided support for its high-quality growth. Accompanying the delegation were Gao Dongmei, Member of the Party Leadership Group and Director of the Office of the District People’s Congress Standing Committee; Li Hong, Party Secretary and Director of the District Finance Bureau; and Sun Luofu, Party Secretary and Director of the District Industrial Promotion Center. Upon arriving at Minhai Bio, the delegation inspected the company’s production and R&D operations and gained a detailed understanding of its latest achievements in vaccine development, manufacturing processes, international cooperation, and other areas.

22

2026-01


The company’s internal publication, “Minhai People”

1. On a computer, open this link https://flbook.com.cn/make/be2zyBpgVf to view the desktop display. 2. Use WeChat to scan the QR code in the attachment to view the mobile display.

05

2026-01


Good News | Minhai Bio Honored with the 2025 Beijing “Low-Carbon Leader” Title

Recently, the Beijing Municipal Ecology and Environment Bureau officially released the list of “Beijing Low-Carbon Leaders” for 2025, which includes a total of six companies. Beijing Minhai Biotechnology Co., Ltd. (hereinafter referred to as “Minhai Bio”) was successfully selected for this honor thanks to its outstanding achievements in green manufacturing and energy conservation and carbon reduction, becoming the only enterprise in Daxing District to receive this distinction this year. This recognition marks another significant milestone for Minhai Bio on its sustainable development journey, following its earlier designation as a “National-Level Green Factory,” further solidifying its position as a leading benchmark for low-carbon development in the biopharmaceutical industry. Systematic carbon reduction: spanning the entire value chain—from R&D and production to operations.

18

2025-12


Kangtai Biological’s 60-microgram hepatitis B vaccine for “preventing viral rebound” has received clinical trial approval, offering a globally innovative strategy that could pave the way for functional cure of chronic hepatitis B.

Recently, the recombinant hepatitis B vaccine (Saccharomyces cerevisiae) (60 μg), developed by Kangtai Biological, received a “Notice of Approval for Clinical Trials” from the National Medical Products Administration, approving the initiation of a clinical trial to prevent HBsAg re‑positive conversion in individuals who have achieved functional (clinical) cure of chronic hepatitis B. The 60‑microgram hepatitis B vaccine, whose supplemental clinical application has now been approved, works by inducing high levels of anti‑HBs antibodies and establishing long‑lasting immune memory, thereby helping those who have cleared chronic HBsAg maintain a sustained state of functional cure—essentially preventing HBsAg re‑positive conversion. In terms of pipeline positioning, the latter…

02

2025-12


Senior executives of Kangtai Minhai have been awarded the “Outstanding Achievement Award” at the 19th Pharmaceutical Development Awards.

On November 28, 2025, the 19th Pharmaceutical Development Award Ceremony was held in Beijing. Attending the event were former State Councilor and Vice Chairperson of the Standing Committee of the 11th National People’s Congress Chen Zhili, as well as Academicians Zhang Boli, Chen Kaixian, Zhang Gaiping, Yue Jianmin, Wang Junzhi, and Xia Ningshao, along with more than 300 experts and scholars from renowned universities, research institutions, and medical organizations. Liu Jiankai, Director and Vice President of Kintor Pharmaceutical and Executive Deputy General Manager of Minhai Biotechnology, was awarded the “Outstanding Achievement Award.” The Pharmaceutical Development Award, established in 1994 under the Office of National Science and Technology Awards, recognizes contributions in the field of medicine and pharmacy.

< 1234...31 >